Randomized, double-blind, placebo controlled, phase 2 study of pemetrexed and cisplatin plus enzastaurin versus pemetrexed and cisplatin plus placebo in chemonaive patients with advanced, unresectable, or metastatic (stage IIIB or IV) non-small cell lung cancer

Trial Profile

Randomized, double-blind, placebo controlled, phase 2 study of pemetrexed and cisplatin plus enzastaurin versus pemetrexed and cisplatin plus placebo in chemonaive patients with advanced, unresectable, or metastatic (stage IIIB or IV) non-small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2012

At a glance

  • Drugs Cisplatin; Enzastaurin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2012 Results published in Oncology.
    • 12 Oct 2009 Tolerability results have been presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
    • 11 Dec 2008 Actual patient number (27) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top